News by National Association of Boards of Pharmacy. & Massachusetts. Board of Registration in Pharmacy.
MA Vol. 1, No. 3 Page 1
Naloxone Standing Orders
Now that all pharmacies licensed by the Massachusetts 
Board of Registration in Pharmacy must maintain a naloxone 
standing order and a sufficient supply to meet the needs of 
the community, naloxone may be dispensed to any person 
at risk for an opioid-related overdose or to family members, 
friends, or others in a position to assist a person at risk for 
an opioid-related overdose. 
Patient-specific prescriptions from practitioners may still 
be honored.
Here are some helpful notes to be aware of: 
♦ Standing orders must be renewed every two years.
♦ Label the naloxone rescue kits with the expiration
date of the drug.
♦ The phrase “Naloxone Rescue Kit” may be used to
create a patient profile and prescription label.
♦ With the purchaser’s permission, contact his or her
insurance company to verify coverage.
♦ Distribute the administration pamphlet at the time of
dispensing. The pamphlet may be downloaded at www
.mass.gov/eohhs/docs/dph/quality/boards/pharmacy/
naloxone-pamphlet.pdf.
♦ By January 15, the number of naloxone units dispensed
under the standing order for the previous calendar
year must be reported to naloxonestandingorders@
massmail.state.ma.us.
♦ See Policy 2017-03 for full details at https://www.mass
.gov/files/documents/2017/10/12/policy-2017-03.pdf.
Inspection Tools
Located on the Board’s website are the tools used by 
pharmacy investigators during inspections. Whether your 
facility is a wholesale distributor, sterile compounder, 
complex sterile compounder, or typical retail pharmacy, the 
tools may be found at https://www.mass.gov/lists/pharmacy-
practice-resources.
Managers of record (MORs) are encouraged to perform 
self-inspections utilizing these tools prior to taking on 
the managerial role, and periodically thereafter, to ensure 
compliance. Sharing this information with staff, including 
interns, will help them understand what is expected in terms 
of compliance. 
Attached to the end of the United States Pharmacopeia 
(USP) Chapter <795> and USP Chapter <797> inspection 
tools are checklists itemizing the documents that will be 
requested during Board inspections. Preparing for inspec-
tion by having these documents readily available can help 
expedite the process.
Prescription Monitoring Program
Pharmacists are on the front lines to help identify concern-
ing activity that may suggest inappropriate prescribing or 
potential abuse/misuse of prescribed medications. 
What Can a Pharmacist Do?
♦ Register for and routinely use the online Massachusetts
Prescription Awareness Tool.
♦ Look for suspicious things such as overlapping
prescriptions, excessively high morphine milligram
equivalents, and dangerous drug combinations.
♦ Be aware of certain patient behaviors, including paying
in cash, refusing to provide a photo ID at pick up, or
picking up prescriptions for multiple patients.
♦ For patients who concern you and your staff, talk to
the patients themselves and/or their prescribers.
♦ Call local police if you suspect criminal behavior.
♦ Visit the Massachusetts Prescription Monitoring
Program (PMP) website to register and obtain more
information: https://www.mass.gov/prescription-
monitoring-program-pmp.
Data Submission to the PMP
The accuracy and timeliness of pharmacies’ prescription 
data submissions are the backbone of the PMP. Timely re-
porting can prevent a prescriber from writing a potentially 
harmful prescription. When in doubt, refer to the Data 
Submission Dispenser Guide, available at www.mass.gov/
eohhs/docs/dph/quality/drugcontrol/pmp/pmp-dispenser-
guide.pdf. The law requires you to report all Schedule II 
through V controlled substances (CS), as well as gabapentin, 
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prescription drug monitoring program (PDMP) data to 
identify prescribing patterns that place patients at risk for 
opioid use disorder and overdose and to target interven-
tions with prescribers based on opioid prescribing guide-
lines. The July 7, 2017 Morbidity and Mortality Weekly 
Report, “Vital Signs: Changes in Opioid Prescribing in 
the United States, 2006–2015,” can be accessed on the 
CDC website at www.cdc.gov/mmwr/index.html in the 
Weekly Report section.
AMA Opioid Task Force Encourages 
Co-Prescribing Naloxone to At-Risk 
Patients
The American Medical Association (AMA) Opioid 
Task Force encourages physicians to consider co-
prescribing naloxone when it is clinically appropriate to 
do so. The AMA Opioid Task Force offers several ques-
tions for determining whether to co-prescribe naloxone 
to a patient or a patient’s family member or close friend, 
which may be found in the August 2017 document, “AMA 
Opioid Task Force naloxone recommendations,” avail-
able on the AMA opioid microsite at https://www.end-
opioid-epidemic.org.
The Naloxone section of the AMA opioid micro-
site also offers physicians multiple resources on co- 
prescribing naloxone in their practice and community. 
To help end the opioid epidemic, the AMA Opioid Task 
Force made several recommendations for physicians, 
including registering and using state PDMPs, training and 
education on evidence-based treatment, and promoting 
safe storage and disposal of opioids and medications.
Opioid Addiction Medications Should 
Not Be Withheld From Patients Taking 
Benzodiazepines or CNS Depressants
Opioid addiction medications – buprenorphine and 
methadone – should not be withheld from patients taking 
benzodiazepines or other drugs that depress the central 
nervous system (CNS), advises FDA. The combined use 
of these drugs increases the risk of serious side effects; 
however, the harm caused by untreated opioid addic-
tion usually outweighs these risks. Careful medication 
management by health care providers can reduce these 
risks, notes a safety alert. FDA is requiring this informa-
tion to be added to the buprenorphine and methadone 
drug labels along with detailed recommendations for 
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FDA Draft Guidance Addresses Delayed 
Enforcement of DSCSA Requirements 
for Product Identifiers 
Food and Drug Administration (FDA) issued a draft 
guidance for industry that informs manufacturers and 
other supply chain stakeholders that although manu-
facturers are to begin including a product identifier on 
prescription drug packages and cases on November 27, 
2017, FDA is delaying enforcement of those require-
ments until November 2018 to provide manufacturers 
additional time and avoid supply disruptions. The com-
pliance policy outlined in the June 2017 draft guidance, 
Product Identifier Requirements Under the Drug Supply 
Chain Security Act – Compliance Policy, applies solely to 
products without a product identifier that are introduced 
into commerce by a manufacturer between November 
27, 2017, and November 26, 2018. While manufactur-
ers work to meet product identifier requirements, they 
must comply with other Drug Supply Chain Security 
Act (DSCSA) requirements. The draft guidance can be 
accessed from FDA’s website at www.fda.gov/Drugs/
DrugSafety/DrugIntegrityandSupplyChainSecurity/
DrugSupplyChainSecurityAct/ucm565358.htm.
Amount of Prescribed Opioids Remains 
High, Reports CDC
The amount of opioids prescribed remains approxi-
mately three times as high as in 1999, despite reductions 
in each year after 2010 through 2015. Centers for Disease 
Control and Prevention (CDC) researchers analyzed 
retail prescription data to assess opioid prescribing in 
the United States from 2006 to 2015 and county-level 
prescribing patterns in 2010 and 2015. According to a 
CDC report, results of the study showed higher amounts 
of opioids were prescribed in counties that had a greater 
percentage of non-Hispanic white residents, a higher 
prevalence of diabetes and arthritis, micropolitan status 
(ie, town/city; nonmetro), and higher unemployment and 
Medicaid enrollment rates. The researchers conclude that 
health care providers should carefully weigh the benefits 
and risks when prescribing opioids outside of end-of-
life care, follow evidence-based guidelines (eg, CDC’s 
Guideline for Prescribing Opioids for Chronic Pain), and 
consider non-opioid therapy for chronic pain treatment.
Additionally, the researchers conclude that state and 
local jurisdictions can use these findings along with 
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minimizing the use of medication-assisted treatment 
drugs and benzodiazepines together.
Health care providers should take several actions and 
precautions and should develop a treatment plan when 
buprenorphine or methadone is used in combination 
with benzodiazepines or other CNS depressants. Addi-
tional information may be found in an FDA Drug Safety 
Communication announcement at www.fda.gov/Drugs/
DrugSafety/ucm575307.htm. 
New Study Shows Substantial Variation 
in the Availability of Pharmacies Across 
the Country
Despite the rising number of US pharmacies from 
2007 to 2015, the availability of pharmacies varied 
significantly across local areas, indicates a new study. 
The study, The availability of pharmacies in the United 
States: 2007–2015, found that the number of commu-
nity pharmacies increased 6.3% from 63,752 to 67,753 
between 2007 and 2015. Although the number of pharma-
cies per capita remained at 2.11 per 10,000 individuals 
between 2007 and 2015, the researchers found substan-
tial variation across counties. “Some counties have 13 
pharmacies per capita, while others have none,” said 
Dima Qato, lead study author and assistant professor of 
pharmacy systems, outcomes and policy, in a University 
of Illinois at Chicago (UIC) news release.
In 2015, counties in the highest quintile had nearly 
three-fold more pharmacies than those in the lowest 
quintile. Counties in the lowest quintile are located in 
the Pacific West, Southwest, and Great Lakes regions, 
while counties with the highest tend to be located in the 
Northeast, Southeast, Northern Appalachia, and Plains 
states. The researchers conclude that future programs 
and policies should address the availability of pharma-
cies and ensure that pharmacy characteristics, including 
accommodations such as multilingual staffing and home 
delivery, align with local population needs.
To view the study, visit https://doi.org/10.1371/ 
journal.pone.0183172. The UIC news release is available 
at https://today.uic.edu/access-to-pharmacies-limited-to-
some-patients.
Consent Decree Entered Against 
Outsourcing Facility Isomeric 
Pharmacy Solutions
Under a consent decree of permanent injunction 
entered in August 2017, Isomeric Pharmacy Solutions 
of Salt Lake City, UT, its owners, and chief operating 
officer are prohibited from manufacturing, process-
ing, packing, holding, or distributing drugs until they 
comply with the Federal Food, Drug, and Cosmetic Act 
(FD&C Act) and its regulations, in addition to other 
requirements. Isomeric manufactured and distributed 
purportedly sterile drug products, including injectable 
and ophthalmic drugs, that were adulterated because 
the drugs were made under insanitary conditions and 
in violation of current good manufacturing practice 
requirements under the FD&C Act, according to the 
complaint for permanent injunction. The complaint also 
alleges that Isomeric manufactured and distributed un-
approved drugs and drugs that were misbranded because 
their labeling did not bear adequate directions for use. 
Isomeric initially registered as an outsourcing facility 
in July 2015 and reregistered in December 2015 and 
January 2017. Additional information is available in 
an FDA news release at www.fda.gov/NewsEvents/ 
Newsroom/PressAnnouncements/ucm570130.htm.
FDA Issues Warning on Alcohol Pads 
or Benzalkonium Chloride Antiseptic 
Towelettes Made by Foshan
In September 2017, FDA alerted health care providers 
and patients to not use alcohol pads or benzalkonium 
chloride antiseptic towelettes made by Foshan Flying 
Medical Products Co, Ltd, located in China, due to lack 
of sterility assurance and other quality issues. These 
products are distributed by Total Resources International, 
of Walnut, CA, and Simple Diagnostics, Inc, of Williston 
Park, NY. The use of these alcohol pads and antiseptic 
towelettes could cause infections.
FDA placed all drug products made by Foshan on 
import alert on May 23, 2017, to stop these products 
from entering the US. However, FDA is concerned these 
products might still be in distribution in the US. FDA 
also sent Foshan a warning letter on August 1, 2017, for 
violations of current good manufacturing practice regula-
tions. FDA initially contacted Foshan regarding a recall 
on May 25, 2017, and had several follow-up meetings 
with the company. Foshan has not taken action to remove 
its alcohol pads or antiseptic towelettes from the market. 
The safety alert posted to FDA’s website may be found 
at www.fda.gov/Safety/MedWatch/SafetyInformation/
SafetyAlertsforHumanMedicalProducts/ucm574576.htm.
Pharmacies and health care facilities that have alcohol 
pads and antiseptic towelettes labeled by Total Resources 
or Simple Diagnostics should immediately stop using 
them and discard the products. Adverse events or side ef-
fects related to the use of these products may be reported 
to FDA’s MedWatch Safety Information and Adverse 
Event Reporting Program at www.fda.gov/MedWatch/
report.
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electronically at least every 24 hours or the next business 
day. Be sure to have a backup submission plan for vacations 
and sick days!
Quality Related Events and Serious Adverse 
Drug Events
A quality related event (QRE) is the incorrect dis-
pensing of a prescribed medication that is received by 
a patient. All Board-licensed pharmacies must establish 
and maintain a continuous quality improvement (CQI) 
program for the purpose of detecting, documenting, 
assessing, and preventing QREs. The regulation concern-
ing CQI programs is available for download at https://www 
.mass.gov/regulations/247-CMR-1500-continuous-quality-
improvement-program.
A designated person(s) must be responsible for monitor-
ing CQI program compliance and provide ongoing staff 
education. 
QREs must be brought to the attention of a pharmacist 
immediately upon discovery so that the patient, his or her 
representative, and the prescriber (if necessary) may be 
immediately notified. A plan for correcting the error and 
instructions for minimizing any negative effects on the 
patient must be implemented immediately. All communica-
tions must be documented either manually or electronically.
QREs must be investigated and analyzed, both individ-
ually and collectively, to assess causes and contributing 
factors such as system or process failures. This is also 
recommended for the purpose of analyzing and assessing 
“near misses.”
Policies and procedures should be developed requir-
ing that incident reports be completed and submitted to a 
national database, such as the Institute for Safe Medica-
tion Practices Medication Errors Reporting Program or 
another patient safety organization. Institute a system to 
review QREs at least quarterly to identify trends and make 
improvements. 
Additionally, any serious adverse drug event resulting 
in serious injury or death that was caused by a compounded 
preparation (sterile or nonsterile) or a dispensing error must 
be reported within seven business days of discovery using a 
Reporting of Serious Adverse Drug Events form, available 
at www.mass.gov/eohhs/docs/dph/quality/boards/pharmacy/
sade-reporting.pdf.
Manager of Record Changes 
Accepting an MOR position in a Massachusetts-licensed 
pharmacy is truly an important decision. At the Board, we 
find that most pharmacy managers accept the responsibility 
seriously and do a great job ensuring full compliance with 
Massachusetts regulations (247 Code of Massachusetts Reg-
ulations) and Drug Enforcement Administration regulations. 
Occasionally, the Board encounters a manager who either 
is unfamiliar with the expectations and requirements of the 
role or does not fully understand the level of accountability. 
In August 2017, the Board adopted an advisory to help 
guide managers in their obligations. All MORs, whether new 
or well-seasoned in the role, should periodically review it: 
www.mass.gov/eohhs/docs/dph/quality/boards/pharmacy/
advisories/new-managers-record.pdf.
The main thing to remember is that someone needs to be 
responsible for the licensed facility at all times. Should the 
current MOR leave the position, even temporarily (30-100 
days), the Board should be notified immediately with the 
name of an “interim manager.” 
Prior to his or her absence, an MOR must perform a CS 
inventory that is signed by the MOR and the interim man-
ager. If the MOR is unexpectedly not available, another 
registered pharmacist must perform the CS inventory with 
the interim manager.
If you are the outgoing manager, you should personally 
notify the Board (via email) as well. Everything in that 
pharmacy remains your responsibility until the Board has 
been informed otherwise. 
Remember that the Board must be notified within 10 days 
of the start or termination of a specific MOR’s employment.
The Application for Change in Manager of a Pharmacy 
may be found at www.mass.gov/eohhs/docs/dph/quality/
boards/pharmacy/pharmacy-change-manager.pdf.
The Board now requires random MOR applicants to 
appear before the Board to answer questions from Board 
members. Make sure your continuing education credits are 
up to date!
Did You Know?
 ♦ You can email the Board with practice questions at 
pharmacy.admin@massmail.state.ma.us. 
 ♦ Best practice recommendations may be found at https://
www.mass.gov/files/2017-08/pharmacy-best-practice.doc.
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